REDOXIS AB

Their core work

REDOXIS AB is a Swedish biotech SME specializing in redox biology — the study of how reactive oxygen species (ROS) influence disease and health. They develop knowledge and tools around ROS-based mechanisms in immune cells, particularly neutrophils, with applications in autoimmune diseases and cancer. Their work bridges fundamental immunology research with translational medicine, contributing specialized redox chemistry expertise to large European research consortia focused on immune system disorders.

What they specialise in

How they've shifted over time

REDOXIS began with broad ROS research in chronic disease (REDOXIT, 2015), then moved into computational and systems-level understanding of immune disorders through COSMIC (2018). Their most recent and largest project, NeutroCure (2020), combines both threads into a more applied direction: engineering targeted ROS-based interventions for neutrophil-driven autoimmunity and cancer. The trajectory shows a clear shift from foundational redox biology toward therapeutic applications.

REDOXIS is moving from basic redox science toward applied, disease-specific interventions — their next logical step would be preclinical or clinical translation of ROS-based therapies.

How they like to work

REDOXIS operates exclusively as a participant, never leading consortia — consistent with a small specialized SME contributing domain expertise rather than managing large projects. They have worked with 30 unique partners across 11 countries in just 3 projects, indicating they join broad, well-connected consortia rather than tight-knit repeating teams. This suggests they are valued for specific technical contributions and are easy to integrate into new partnerships.

Despite only 3 projects, REDOXIS has built a network of 30 partners across 11 countries, reflecting the large consortium sizes typical of MSCA and RIA programmes. Their network is strongly European with no evident geographic concentration beyond their Swedish base.

What sets them apart

REDOXIS occupies a rare niche: a private SME with deep expertise in redox biology and ROS mechanisms, a field dominated by academic groups. Their company name itself signals total commitment to this domain. For consortium builders, they offer an industry partner that genuinely understands ROS biochemistry at research level — useful for projects requiring private-sector participation without sacrificing scientific depth.

Highlights from their portfolio

• NeutroCure
  Their largest project (EUR 400,000) and most translational — developing targeted ROS amplifiers for neutrophil-driven autoimmune disease and cancer.
• COSMIC
  Applied systems medicine to B cell disorders including rheumatoid arthritis and B-cell neoplasia, combining computational and experimental immunology.